Últimas noticias sobre TransMedics Gr (NASDAQ:TMDX) Bolsa

TransMedics Gr

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group

TransMedics Group Inc

News

LNZA

Technip Energies And LanzaTech Secure $200M U.S. DOE Funding To Advance CO2-To-Ethylene Technology With Initial $20M For Phase 1 Engineering And Community Engagement

Federal Reserve

Powell Says Labor Market Not Cooling In A Way That Raises Concerns

<p>Across the recent three months, 11 analysts have shared their insights on Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Nevro, presenting an average target of $5.34, a high estimate of $7.00, and a low estimate of $4.00. Experiencing a 21.35% decline, the current average is now lower than the previous average price target of $6.79. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552064_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Nevro is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.70</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nevro. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Nevro's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nevro's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nevro analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Nevro</h2>
<p>Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.</p>
<h3>Understanding the Numbers: Nevro's Finances</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Nevro faced challenges, resulting in a decline of approximately <strong>-6.69%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Nevro's net margin excels beyond industry benchmarks, reaching <strong>-15.83%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-5.6%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Nevro's ROA excels beyond industry benchmarks, reaching <strong>-2.56%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Nevro's debt-to-equity ratio is below the industry average. With a ratio of <b>0.9</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

NVRO

Where Nevro Stands With Analysts

<p>In the latest quarter, 6 analysts provided ratings for DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.33, a high estimate of $107.00, and a low estimate of $84.00. This current average has increased by 0.17% from the previous average price target of $94.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552053_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive DuPont de Nemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$84.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DuPont de Nemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DuPont de Nemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for DuPont de Nemours's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DuPont de Nemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DuPont de Nemours analyst ratings.</strong></a></p>
<h2>Get to Know DuPont de Nemours Better</h2>
<p>DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to separate the company into three companies going forward, one focused on electronics, one focused on water, and one with more diversified end market exposure. We expect the separations will occur by mid-2026.</p>
<h3>DuPont de Nemours: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, DuPont de Nemours showcased positive performance, achieving a revenue growth rate of <strong>4.38%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> DuPont de Nemours's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>14.22%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DuPont de Nemours's ROE excels beyond industry benchmarks, reaching <strong>1.91%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> DuPont de Nemours's ROA excels beyond industry benchmarks, reaching <strong>1.23%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.29</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying DuPont de Nemours: Insights From 6 Analyst Reviews

<p>4 analysts have shared their evaluations of FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated FMC and provided 12-month price targets. The average target is $68.25, accompanied by a high estimate of $81.00 and a low estimate of $55.00. This current average has decreased by 3.42% from the previous average price target of $70.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552043_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive FMC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Parkinson</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$67.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FMC. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FMC compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into FMC's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FMC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on FMC analyst ratings.</strong></a></p>
<h2>About FMC</h2>
<p>FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.</p>
<h3>FMC's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> FMC's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>8.5%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> FMC's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.08%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> FMC's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> FMC's ROA excels beyond industry benchmarks, reaching <strong>0.53%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> FMC's debt-to-equity ratio surpasses industry norms, standing at <strong>0.88</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For FMC

<p>Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $319.65, a high estimate of $350.00, and a low estimate of $270.00. Marking an increase of 6.35%, the current average surpasses the previous average price target of $300.56. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552034_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Monday.Com's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Lucky Schreiner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Iwanyc</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$340.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Connor Murphy</td>
<td>Capital One</td>
<td>Announces</td>
<td>Overweight</td>
<td>$325.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$327.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Monday.Com. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Monday.Com's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Monday.Com's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Monday.Com analyst ratings.</strong></a></p>
<h2>Discovering Monday.Com: A Closer Look</h2>
<p>Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.</p>
<h3>Monday.Com's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Monday.Com showcased positive performance, achieving a revenue growth rate of <strong>32.67%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Monday.Com's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-4.79%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.28%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Monday.Com's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.79%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Monday.Com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.09</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MNDY

17 Analysts Assess Monday.Com: What You Need To Know

<p>During the last three months, 4 analysts shared their evaluations of Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Treace Medical Concepts and provided 12-month price targets. The average target is $7.6, accompanied by a high estimate of $8.40 and a low estimate of $6.00. This upward trend is evident, with the current average reflecting a 6.0% increase from the previous average price target of $7.17.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552024_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Treace Medical Concepts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.40</td>
<td>$7.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Treace Medical Concepts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Treace Medical Concepts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Treace Medical Concepts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Treace Medical Concepts's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TMCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Treace Medical Concepts analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Treace Medical Concepts</h2>
<p>Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.</p>
<h3>Unraveling the Financial Story of Treace Medical Concepts</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Treace Medical Concepts displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.62%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Treace Medical Concepts's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-34.07%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Treace Medical Concepts's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-14.15%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-7.0%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Treace Medical Concepts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.67</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TMCI

Deep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings)

Macro Economic Events

Economics

Powell Says It Might Take Another Year Or Two From Here To Get To 2%

<p>8 analysts have shared their evaluations of MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.38, along with a high estimate of $55.00 and a low estimate of $43.00. Surpassing the previous average price target of $49.14, the current average has increased by 4.56%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552013_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of MPLX among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MPLX. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MPLX compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for MPLX's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MPLX's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MPLX analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind MPLX</h2>
<p>MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.</p>
<h3>Breaking Down MPLX's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> MPLX displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.28%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>37.14%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MPLX's ROE excels beyond industry benchmarks, reaching <strong>7.52%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MPLX's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.68%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> MPLX's debt-to-equity ratio is below the industry average at <strong>1.66</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MPLX

What Analysts Are Saying About MPLX Stock

Powell Says Housing Inflation Has Come Down Steadily,  Goods Inflation Has Returned To Pre-Pandemic Range Overall

<p><em>Editor's Note: The spelling of Michael Saylor&#8217;s name has been corrected in the headline.</em></p>
<p>Financial market commentator <strong>Peter Schiff</strong> on Tuesday criticized <strong>Michael Saylor&#8217;s </strong>comparison of <strong>MicroStrategy Inc.</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-financed <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy to Manhattan real estate.</p>
<p><strong>What Happened</strong>: In an X post, Schiff disagreed with Saylor&#8217;s analogy. &#8220;Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#8217;t generate any income to make interest or principal payments,&#8221; he argued.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">It&#39;s wrong for <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> to compare his leveraged buying of <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> to investors borrowing money to purchase Manhattan real estate. Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#39;t generate any income to make interest or principal payments.</p>
<p>&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1869116244714262623?ref_src=twsrc%5Etfw">December 17, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Spencer Hakimian</strong>, founder of hedge fund <strong>Tolou Capital Management</strong>, countered Schiff&#8217;s viewpoint, stating that, unlike the Manhattan real estate industry, Bitcoin doesn&#8217;t have any expenses or maintenance.</p>
<p>Schiff responded that rents from real estate exceed the expenses.</p>
<p>The city&#8217;s rental market contradicts national trends, with the top 50 markets experiencing 15 consecutive months of rent decreases. In October 2024, New York&#8217;s <a href="https://www.benzinga.com/real-estate/24/12/42256888/as-nyc-rents-hit-new-highs-85-of-residents-look-to-buy-elsewhere-heres-what-they-find">median asking rent</a> increased 1.7% year-on-year to $3,374, representing a 13.1% increase from pre-pandemic values. Manhattan&#8217;s median monthly rent stood at $4,750 as of this writing, according to Realtor.com.</p>
<p><strong>See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42544639/moonpay-partners-with-element-wallet-to-boost-core-token-access-in-btcfi-ecosystem">MoonPay Partners With Element Wallet To Boost Core Token Access In BTCfi Ecosystem</a></strong></p>
<p><strong>Why It Matters</strong>: This criticism comes after Saylor defended MicroStrategy&#8217;s Bitcoin acquisition strategy by equating it to Manhattan&#8217;s real estate industry. He said that <a href="https://www.benzinga.com/24/12/42524546/michael-saylor-counters-critics-who-label-microstrategys-bitcoin-play-ponzi-scheme-calls-it-similar-to-manhattans-real-estate-developers-using-debt-to-build-more-skyscrapers">just like developers in Manhattan issue more debt </a>to develop more real estate when its value goes up, MicroStrategy capitalizes on high returns from Bitcoin to buy more Bitcoin.</p>
<p>Schiff&#8217;s critique adds to the ongoing debate around MicroStrategy&#8217;s Bitcoin strategy. Earlier, he <a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy">warned that the</a> company's commitment to repay a large sum of money to convertible note holders could be a potential risk if the price of Bitcoin falls sharply.</p>
<p>Well-known cryptocurrency analyst <strong>Willy Woo</strong> also <a href="https://www.benzinga.com/24/11/42228264/crypto-analyst-flags-convertible-debt-induced-liquidation-risk-to-michael-saylors-microstrategy">flagged the risk </a>associated with the firm&#8217;s convertible debt offerings, stating that if buyers do not convert to shares&nbsp;before maturity, MicroStrategy would be forced to sell Bitcoin to repay them.</p>
<p><strong>Price Action</strong>:&nbsp; At the time of writing, Bitcoin was exchanging hands at $105,351.94, down 0.86% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. </p>
<p>Shares of MicroStrategy closed 5.41% lower at $ 386.42 during Tuesday&#8217;s regular session. The stock has a <a href="https://www.benzinga.com/quote/MSTR">consensus price target </a>of $449.5 based on the ratings of 12 analysts, with an average price target of $546.67 between&nbsp;<strong>Bernstein</strong>,&nbsp;<strong>TD Cowen</strong>, and&nbsp;<strong>Barclays</strong>.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42538636/pudgy-penguin-token-launches-at-2-billion-valuation-could-land-between-shiba-inu-and-dogecoin-trader-says">Pudgy Penguin Token Launches At $2 Billion Valuation, Could Land &#8216;Between Shiba Inu And Dogecoin,&#8217; Trader Says</a></strong></li>
</ul>
<p><em>Image via Flickr/ Gage Skidmore</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

MSTR

Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: 'BTC Doesn't Generate Any Income' (CORRECTED)

Powell Says Outlook Is Bright For Economy, Want To Keep Labor Market Pretty Close Where It Is; Says Job Creation Is A Little Below Level

Powell Says Core Inflation Coming Down To 2.5% Next Year, Would Be Significant Progress

Powell Says Committee Discussing Ways Tariffs Can Drive Inflation, Says Puts Fed In Place To Make A Careful Assessment Of Appropriate Policy Response To Tariffs; Says Many Factors Affect How Much Tariffs Will Go Into Consumer Inflation, Premature To Make Conclusion

<p>Baird analyst Ben Kallo is reassessing the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle landscape</a> in light of geopolitical uncertainty and policy changes. </p>
<p>Here are two EV players attempting to navigate the turns ahead in 2025.</p>
<h2 class="wp-block-heading">Tesla</h2>
<p><strong>Tesla, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remains a top pick with Baird emphasizing its long-term potential despite near-term volatility. The stock, up nearly 91% since the election, has momentum, Kallo says:</p>
<ul>
<li><strong>New Models:</strong> Upcoming vehicles, including the lower-cost &#8216;Model 2&#8217; and Cybertruck, promise to drive volume growth.</li>
<li><strong>Cost Efficiencies:</strong> Falling production costs and increased factory utilization are expected to boost margins.</li>
<li><strong>Regulatory Tailwinds:</strong> While the removal of the EV tax credit is a negative for the sector, Tesla's competitors are likely to feel the pinch more.</li>
<li><strong>AI and Autonomy:</strong> Investments in full self-driving (FSD), Dojo compute, and the Optimus robot could redefine the EV market.</li>
</ul>
<p>However, Tesla's valuation, geopolitical risks tied to its Shanghai operations, and potential delays in autonomy initiatives are points of caution. </p>
<p>Kallo suggests buying on pullbacks, underlining Tesla's strong position as a market leader.</p>
<p><strong>Read Also: <a href="https://benzinga.com/news/24/12/42515720/whats-going-on-with-rivian-rivn-stock">What&#8217;s Going On With Rivian (RIVN) Stock?</a></strong></p>
<h2 class="wp-block-heading">Rivian</h2>
<p><strong>Rivian Automotive, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) faces a tougher road ahead, earning a downgrade to Neutral.</p>
<p>This downgrade reflects a challenging near-term outlook. Despite a strong brand and promising long-term potential, Kallo highlights several hurdles:</p>
<ul>
<li><strong>Demand Concerns:</strong> EV sales may fall short of expectations in 2025, dampening momentum.</li>
<li><strong>Production Challenges:</strong> Limited ability to leverage fixed costs due to lower production volumes.</li>
<li><strong>Few Catalysts:</strong> With the Volkswagen joint venture finalized and DOE funding secured, Rivian lacks clear drivers for growth next year.</li>
</ul>
<p>While Kallo remains optimistic about Rivian's R2 lineup and its long-term opportunity. But skepticism around near-term profitability and margins led to the Neutral rating.</p>
<h2 class="wp-block-heading">The Big Picture</h2>
<p>As the EV market faces headwinds from policy uncertainty and evolving global dynamics, Tesla continues to dominate while Rivian, though promising, has more to prove in the near term. </p>
<p>For investors, it's a tale of two trajectories—one accelerating confidently, the other stuck in neutral.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/tech/24/12/42548657/tesla-design-chief-says-ev-giant-was-looking-to-create-future-version-of-nycs-yellow-cabs-with-gold-cybercab-it-feels-right">Tesla Design Chief Says EV Giant Was Looking To Create &#8216;Future Version&#8217; Of NYC&#8217;s Yellow Cabs With Gold Cybercab: &#8216;It Feels Right&#8217;</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Long Ideas

Tech

Trading Ideas

RIVN

TSLA

Tesla Remains A Top EV Stock Pick, Rivian Faces Roadblocks: Analyst

<p>Two men from Rochester, New York, met their end after developing a "rare fungal lung infection" linked to using bat guano, or feces, as fertilizer for growing cannabis for their personal use.</p>
<p>The University of Rochester detailed the cases in a <a href="https://academic.oup.com/ofid/article/11/12/ofae711/7917418">report</a> published in <strong>Open Forum Infectious Diseases</strong>, warning that "exposure to bat guano among cannabis growers appears to be a recent trend that can lead to histoplasmosis cases and outbreaks." Histoplasmosis is a lung infection caused by inhaling spores of the Histoplasma fungus. It is also known as the &#8220;cave disease.&#8221;</p>
<p><strong>What Happened</strong>: The first man (59), bought his guano online to use as fertilizer for his cannabis plants. The second man (64), was intending to fertilize his cannabis plants with the bat poop he found in his attic following a heavy bat infestation.</p>
<p>The 59-year-old, a heavy tobacco smoker who had emphysema and arthritis, was hospitalized for respiratory failure after experiencing weight loss, a sore throat and difficulty swallowing over six weeks. A biopsy confirmed histoplasmosis.</p>
<p>The second man, who had vascular disease, reported a "heavy bat infestation" in his attic where he regularly inspected the thick layer of guano, which he intended to use as fertilizer for his cannabis plants, <a href="https://www.livescience.com/health/viruses-infections-disease/bat-poop-used-to-grow-cannabis-kills-2-in-new-york-in-unusual-cases">reported</a> Live Science. He was hospitalized for low sodium levels, chronic coughing and weight loss after initially being treated for histoplasmosis.</p>
<h2 class="wp-block-heading"><strong>Histoplasmosis: Rare But Deadly </strong></h2>
<p>Histoplasmosis is often misdiagnosed or diagnosed too late, which naturally can exacerbate its severity. Symptoms include fever, muscle aches and chest pain. In severe cases, the infection can spread to the brain and spinal cord, causing meningitis. The disease affects an estimated 1 to 2 per 100,000 people annually in the U.S., though researchers suggest the prevalence may be higher due to underreporting or misdiagnosis.</p>
<p>The authors of the report stressed the urgent need for public awareness, particularly as <a href="https://www.benzinga.com/topic/cannabis-legalization">cannabis legalization</a> and the promotion of bat guano fertilizers grow. "Commercial biofertilizers containing bat guano should be tested for [the fungus] before reaching the market," they wrote. "If testing is not feasible, risk mitigation strategies should be implemented.</p>
<p>"The association between histoplasmosis cases and outbreaks with environmental disturbances, particularly in the presence of bat and bird droppings, is well recognized," said the researchers.</p>
<p>They also noted that climate change and bat migration patterns could be adding to an increase in Histoplasma infections. While bats are primary carriers of the fungus, bird droppings can also contribute to its spread.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/24/12/42488355/bird-flu-spreads-to-cats-possibly-horses-as-officials-signal-no-plans-to-authorize-vaccination"><strong>Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination</strong></a></li>
</ul>
<p><em>Photo: Danny Ye/Shutterstock.com</em></p>


Cannabis

Bat Poop Kills 2 Cannabis Farmers In New York From 'Rare' Fungal Infections

Powell Says Higher Inflation Is Probably Biggest Factor For New Projections; Moving Sideways On 12-Month Inflation

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>RH</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RH, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for RH.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 62% bullish and 25%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $87,050, and 5 are calls, for a total amount of $235,910.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $160.0 to $470.0 for RH during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for RH's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of RH's whale trades within a strike price range from $160.0 to $470.0 in the last 30 days. </p>
<h3>RH Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734551138_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$49.7</td>
<td>$49.0</td>
<td>$49.0</td>
<td>$440.00</td>
<td>$98.0K</td>
<td align="right">132</td>
<td align="right">20</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$76.0</td>
<td>$73.2</td>
<td>$76.0</td>
<td>$470.00</td>
<td>$53.2K</td>
<td align="right">186</td>
<td align="right">7</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.7</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$415.00</td>
<td>$32.0K</td>
<td align="right">78</td>
<td align="right">52</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.7</td>
<td>$17.5</td>
<td>$17.7</td>
<td>$430.00</td>
<td>$31.8K</td>
<td align="right">701</td>
<td align="right">32</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$28.8</td>
<td>$28.8</td>
<td>$28.8</td>
<td>$300.00</td>
<td>$28.8K</td>
<td align="right">176</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About RH</h3>
<p>RH is a luxury furniture and lifestyle retailer operating in the $134 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 19 restaurant locations. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade by expanding abroad, with its World of RH digital platform (highlighting offerings outside of home furnishings), and with offerings in bespoke furniture, architecture, media, and more.</p>
<h3>RH's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 458,435, the RH's price is up by 0.55%, now at $414.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 98 days.</li>
</ul>
<h3>What Analysts Are Saying About RH</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $442.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $425.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on RH, maintaining a target price of $435.<br />
&#x2A; An analyst from Loop Capital has decided to maintain their Hold rating on RH, which currently sits at a price target of $450.<br />
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Buy with a new price target of $420.<br />
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for RH, targeting a price of $480. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for RH with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Behind the Scenes of RH's Latest Options Trends

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Qualcomm</strong>.</p>
<p>Looking at options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) we detected 24 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 58% with bearish.</p>
<p>From the overall spotted trades, 15 are puts, for a total amount of $770,801 and 9, calls, for a total amount of $376,265.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $180.0 for Qualcomm, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Qualcomm stands at 1771.79, with a total volume reaching 2,158.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Qualcomm, situated within the strike price corridor from $105.0 to $180.0, throughout the last 30 days.</p>
<h3>Qualcomm 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734551133_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.75</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$165.00</td>
<td>$111.1K</td>
<td>5.6K</td>
<td align="right">484</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.25</td>
<td>$18.75</td>
<td>$18.75</td>
<td>$155.00</td>
<td>$88.1K</td>
<td>2.1K</td>
<td align="right">113</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.45</td>
<td>$7.4</td>
<td>$7.45</td>
<td>$140.00</td>
<td>$83.4K</td>
<td>365</td>
<td align="right">149</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$30.4</td>
<td>$29.4</td>
<td>$29.45</td>
<td>$180.00</td>
<td>$64.7K</td>
<td>470</td>
<td align="right">22</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.8</td>
<td>$8.7</td>
<td>$8.8</td>
<td>$155.00</td>
<td>$64.1K</td>
<td>2.1K</td>
<td align="right">96</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<p>Having examined the options trading patterns of Qualcomm, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Qualcomm Standing Right Now?</h3>
<ul>
<li>With a volume of 3,282,009, the price of QCOM is up 0.09% at $158.07. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 42 days.</li>
</ul>
<h3>Professional Analyst Ratings for Qualcomm</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $183.33333333333334.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $160.<br />
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Qualcomm, targeting a price of $210.<br />
&#x2A; Reflecting concerns, an analyst from Melius Research lowers its rating to Hold with a new price target of $180.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


QCOM

Looking At Qualcomm's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Albemarle</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Albemarle.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 0% bullish and 81%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $65,484, and 9 are calls, for a total amount of $540,108.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $150.0 for Albemarle over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Albemarle stands at 1298.12, with a total volume reaching 1,164.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Albemarle, situated within the strike price corridor from $80.0 to $150.0, throughout the last 30 days.</p>
<h3>Albemarle Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734551128_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.9</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$95.00</td>
<td>$142.8K</td>
<td align="right">245</td>
<td align="right">0</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$35.7</td>
<td>$35.5</td>
<td>$35.5</td>
<td>$80.00</td>
<td>$78.1K</td>
<td align="right">10</td>
<td align="right">29</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$150.00</td>
<td>$75.0K</td>
<td align="right">567</td>
<td align="right">201</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$150.00</td>
<td>$75.0K</td>
<td align="right">567</td>
<td align="right">101</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.45</td>
<td>$12.4</td>
<td>$12.45</td>
<td>$110.00</td>
<td>$37.4K</td>
<td align="right">103</td>
<td align="right">207</td>
</tr>
</tbody>
</table>
</p>
<h3>About Albemarle</h3>
<p>Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.</p>
<p>After a thorough review of the options trading surrounding Albemarle, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Albemarle's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 867,338, the ALB's price is down by -3.59%, now at $94.05. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 56 days.</li>
</ul>
<h3>Professional Analyst Ratings for Albemarle</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $103.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Albemarle with a target price of $103. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Albemarle, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Unpacking the Latest Options Trading Trends in Albemarle

Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on TransMedics Group (TMDX – Research Report) and keeping the price target ...

Positive Outlook for TransMedics Group Amid DCD Market Growth and Transplant Volume Variability

The company recently guided for FY24 revenue of $428M-$432M, consensus $430.97M. Analysts expect the company to report FY25 revenue of $543.99. Gui...

TransMedics sees FY25 revenue growth 20%-25% over midpoint of FY24 guide

Shares of TransMedics (TMDX), whose investor and analyst day began at 10 am ET, are down about 3% to $67.46 in afternoon trading. Published first o...

TransMedics down 3% during analyst day meeting

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on TransMedics Group (TMDX – Research Report). The associated price target remai...

TransMedics Group: Promising Growth Trajectory with Strategic Expansion and Clinical Advancements

Needham analyst Michael Matson has maintained their neutral stance on TMDX stock, giving a Hold rating on December 3. Michael Matson has given his ...

TransMedics Group: Hold Rating Amid Transitional Growth Phase

Piper Sandler analyst Matt O'Brien lowered the firm's price target on TransMedics (TMDX) to $90 from $110 and keeps an Overweight rating on the sha...

TransMedics price target lowered to $90 from $110 at Piper Sandler

Piper Sandler Sticks to Their Buy Rating for TransMedics Group (TMDX)

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target...

TransMedics Group (TMDX) Gets a Buy from Oppenheimer

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on TransMedics Group (TMDX – Research Report) and keeping the price target at $80...

TransMedics Group: Balancing Long-term Promise with Short-term Uncertainty – Hold Rating Maintained

JPMorgan analyst Allen Gong downgraded TransMedics (TMDX) to Neutral from Overweight with a price target of $75, down from $116. The company's near...

TransMedics downgraded to Neutral from Overweight at JPMorgan

TMDX

Legal

Press Releases

INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TMDX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

TMDX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)

TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference

TransMedics to Host Investor & Analyst Day on December 10, 2024

TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Comments

TransMedics Gr

Noticias

Últimas noticias sobre TransMedics Gr (NASDAQ:TMDX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL